{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T21:42:37Z","timestamp":1776462157829,"version":"3.51.2"},"reference-count":56,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.jmoldx.2013.05.010","type":"journal-article","created":{"date-parts":[[2013,7,19]],"date-time":"2013-07-19T20:31:14Z","timestamp":1374265874000},"page":"556-564","source":"Crossref","is-referenced-by-count":31,"title":["Molecular Monitoring of Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"15","author":[{"given":"ChaoJie","family":"Zhen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. Lynn","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2013.05.010_bib1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib3","first-page":"1497","article-title":"Minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib5","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib6","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib7","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib8","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/asheducation-2007.1.376","article-title":"Chronic myeloid leukemia: molecular monitoring in clinical practice","author":"Branford","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2141.1999.01749.x","article-title":"Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics","volume":"107","author":"Branford","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib10","first-page":"160","article-title":"Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia","volume":"9","author":"Kantarjian","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib11","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/sj.leu.2401566","article-title":"Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR","volume":"13","author":"Emig","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib12","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2007-09-110189","article-title":"Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods","volume":"111","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib13","first-page":"3171","article-title":"LightCycler technology for the quantitation of bcr\/abl fusion transcripts","volume":"59","author":"Kreuzer","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/gcc.1171","article-title":"Chronic myelogenous leukemia: laboratory diagnosis and monitoring","volume":"32","author":"Wang","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib15","first-page":"138","article-title":"Molecular monitoring of BCR-ABL transcripts: standardization needed to properly use, and further investigate the value of, a critical surrogate marker for success in therapy of chronic myeloid leukemia","volume":"7","author":"Giles","year":"2011","journal-title":"US Oncol Hematol"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.beha.2009.10.001","article-title":"Response definitions and European Leukemianet Management recommendations","volume":"22","author":"Baccarani","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib18","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib19","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib20","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","article-title":"Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate","volume":"11","author":"Cortes","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib21","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib22","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: eNESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib23","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib24","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib25","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib27","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib28","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1182\/asheducation-2009.1.477","article-title":"Monitoring disease response to tyrosine kinase inhibitor therapy in CML","author":"Hughes","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib29","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib30","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.leu.2404139","article-title":"Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL","volume":"20","author":"Ross","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib31","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib33","doi-asserted-by":"crossref","first-page":"7389","DOI":"10.1038\/sj.onc.1206942","article-title":"Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias","volume":"22","author":"Shah","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib34","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2353\/jmoldx.2009.080095","article-title":"Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology","volume":"11","author":"Jones","year":"2009","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib36","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(07)70379-0","article-title":"Part II: management of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib37","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib38","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/asheducation-2007.1.384","article-title":"The biology of CML blast crisis","author":"Radich","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"Suppl 2","key":"10.1016\/j.jmoldx.2013.05.010_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428190903370387","article-title":"State-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment","volume":"50","author":"Aguayo","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib40","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib41","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib42","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib43","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clml.2011.01.001","article-title":"Translating trial-based molecular monitoring into clinical practice: importance of international standards and practical considerations for community practitioners","volume":"11","author":"Akard","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib44","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2353\/jmoldx.2007.060134","article-title":"Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations","volume":"9","author":"Zhang","year":"2007","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib45","unstructured":"College of American Pathologists (CAP). Minimal Residual Disease (MRD-A) Survey 2012.\u00a02012, Northfield, IL"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib46","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib47","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","article-title":"Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia","volume":"20","author":"Branford","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib48","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib49","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u201creal-time\u201d quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): a Europe against cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib50","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2353\/jmoldx.2006.040404","article-title":"Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts","volume":"8","author":"Wang","year":"2006","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib51","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2353\/jmoldx.2006.050150","article-title":"beta-Glucuronidase is an optimal normalization control gene for molecular monitoring of chronic myelogenous leukemia","volume":"8","author":"Lee","year":"2006","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib52","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1182\/blood-2010-06-291641","article-title":"Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA","volume":"116","author":"White","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib53","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.beha.2009.04.001","article-title":"Standardisation of molecular monitoring for chronic myeloid leukaemia","volume":"22","author":"Cross","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib54","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe","volume":"23","author":"Muller","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib55","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/sj.leu.2404716","article-title":"Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements","volume":"21","author":"Saldanha","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2013.05.010_bib56","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.leukres.2008.06.020","article-title":"Control genes in international standardization of real-time RT-PCR for BCR-ABL","volume":"33","author":"Moravcova","year":"2009","journal-title":"Leukemia Res"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157813001116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157813001116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T19:16:16Z","timestamp":1563477376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157813001116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1525157813001116"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2013.05.010","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}